1. Introduction
===============

Gastric cancer (GC) is one of the most frequent malignant tumors and ranks the third position among main reasons for cancer-related deaths all over the world.^\[[@R1]\]^ Recent years, its high incidence and mortality rates seriously threaten people\'s health.^\[[@R2],[@R3]\]^ Various factors have been reported to be involved in GC tumorigenesis, such as smoking, bacterium infection, diet and genetic components.^\[[@R4]--[@R6]\]^ Up to now, some therapeutic methods were used for cancer treatment, including surgery, chemotherapy, and radiotherapy.^\[[@R7],[@R8]\]^ However, the prognosis of GC patients is still unsatisfactory.^\[[@R9]\]^ Lacking clinical symptoms in early stage, most of GC patients are diagnosed at advanced stage, leading to poor prognosis.^\[[@R10]\]^ Besides, current treatment options are limited and long-term survival is poor. Therefore, improving diagnostic detection and prognostic prediction would be urgent for GC. Great efforts have been made to identify novel prognostic markers which could improve the treatment and survival rate of GC patients.

*G9a* is a histone lysine methyltransferase belonging to Su (Var) 3 to 9 family, and can catalyze dimethylation and histone H3 lysine 9, causing gene silencing at transcriptional level.^\[[@R11]\]^ Evidences indicate that histone methylation is a major reason for the silencing of tumor suppressor genes.^\[[@R12],[@R13]\]^ Thus, *G9a* has been reported to be involved in the progression of different cancers, such as ovarian cancer, lung cancer and so on.^\[[@R14]--[@R16]\]^ Increased expression of G9a in human cancers suggests that it may be a cancer promoter.^\[[@R17],[@R18]\]^ In addition, previous studies on GC reported that the knockdown of *G9a* could induce cell apoptosis in GC,^\[[@R19]\]^ suggesting its crucial role in this malignancy. However, there are few studies on the prognostic significance of *G9a* in GC.

In the present study, we attempted to evaluate the expression patterns of *G9a* and its prognostic value in GC through Kaplan--Meier survival analysis and Cox regression assay.

2. Materials and methods
========================

2.1. Patients and tissue specimens
----------------------------------

In this study we collected 142 GC patients who received surgery at Hubei Cancer Hospital. No cases had received any therapy (chemotherapy or radiotherapy) before operation. One hundred forty-two pairs of GC tissues and adjacent noncancerous tissues (no less than 5 cm from tumor edge) were collected and immediately frozen in liquid nitrogen before stored at −80°C for standby use. All patients were diagnosed by 2 pathologists based on the diagnosis criteria from the World Health Organization. Clinicopathological features of these patients were summarized in Table [1](#T1){ref-type="table"}, including age, gender, disease type, pathological type, differentiation (low grade: well/moderate differentiated and low-grade/moderate malignancy; and high grade: poorly differentiated and high-grade malignancy, based on bipolar grading), lymph node metastasis and TNM stage. Moreover, all of the patients were followed up for 5 years, and relevant information was collected through telephone calls or letters. This research was approved by the Ethics Committee of Hubei Cancer Hospital (approval number: 20150844). Written informed consents were signed by the participators or their families.
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2.2. RNA extraction and qRT-PCR
-------------------------------

TRIzol reagent (Invitrogen, Carlsbad, CA) was adopted to extract total RNA from both cancer tissues and normal samples following the producer\'s instructions. The concentration of RNA was estimated with NanoDrop ND-1000 (NanoDrop, Wilmington, DE). The first chain of cDNA was synthesized using PrimeScript reverse transcriptase (RT) reagent kit (TaKaRa, Shiga, Japan). 7300 Real-Time PCR System (Applied Biosystems, USA) and YBR Green PCR master mix (Applied Biasystems, USA) were applied for qRT-PCR reaction. Primers used in this reaction were designed with Primer Express software. *GAPDH* gene was adopted as the internal control gene to normalize *G9a* expression. Total primers were as follows: *G9a* forward: 5'-TTCAGTCTCTACTATGATTTT-3', reverse: 5'-ATCATAGTAGAGACTGAATT-3'; *GAPDH* forward: 5′-AATGGGCAGCCGTTAGGAAA-3′; reverse: 5′-TGAAGGGGTCATTGATGGCA-3′. Final relative *G9a* expression was calculated with 2^−ΔΔCt^ method.

2.3. Statistical analysis
-------------------------

Statistical analysis was performed with SPSS 18.0 software (SPSS Inc, Chicago, IL). All data in statistical analyses were expressed as mean ± SD. Differences in *G9a* expression between GC tissues and paired noncancerous samples were explored adopting Student *t* test. Chi-square test and *t* test were used to analyze the relationship between *G9a* expression and clinicopathological features of GC patients. GC patients were divided into low- and high-expression groups according to the median of *G9a* expression. Survival analysis was performed with Kaplan--Meier method, and differences were calculated with log-rank test. Cox regression analysis was adopted to assess the prognostic values of *G9a* and clinicopathological characteristics in GC patients. Additionally, ROC (receiver operating characteristic curve) was used to calculate the diagnostic cur-off for *G9a* in GC. Statistical significance was set at *P* \< .05. All experiments were repeated three times.

3. Results
==========

3.1. Increased *G9a* mRNA expression in GC
------------------------------------------

In this study, the expression of *G9a* in tissue samples from 142 GC patients was assessed with qRT-PCR. The results in Figure [1](#F1){ref-type="fig"} indicated that *G9a* expression was higher in GC specimens than in the matched noncancerous ones (*P* \< .001).

![Expression of *G9a* detected by qRT-PCR for 142 pairs of GC specimens and matched noncancerous samples. *G9a* mRNA expression was elevated in GC tissue samples compared with the paired noncancerous tissue specimens (*P* \< .001).](medi-98-e18212-g002){#F1}

3.2. Association of *G9a* expression with clinicopathological features of GC patients
-------------------------------------------------------------------------------------

Using Chi-square test, we investigated the relationship between *G9a* expression and clinicopathological characteristics of GC patients. Clinical information was listed in Table [1](#T1){ref-type="table"}. The results showed that the overexpression of *G9a* was correlated with lymph node metastasis (*P* = .007) and TNM stage (*P* \< .001). However, *G9a* expression was not associated with other clinical features, either age, gender, disease type pathological type or differentiation (all *P* \> .05). Meanwhile, the comparison of *G9a* expression was conducted among GC patient with different ages, genders, disease types, pathological types, differentiation situations, lymph node metastasis statuses and TNM stages through *t* test. The results showed significantly difference in the expression of *G9a* between GC patients with different differentiation situations, lymph node metastasis statuses and TNM stages (*P* \< .05, Fig. [2](#F2){ref-type="fig"}).

![The expression comparison of *G9a* was conducted among GC patient with different age, gender, disease type, pathological type, differentiation, lymph node metastasis and TNM stage. The results showed that the expression of *G9a* between GC patients with different differentiation, lymph node metastasis and TNM stage were significantly different (*P* \< .05).](medi-98-e18212-g003){#F2}

3.3. Elevated G9a expression predicted poor outcomes of GC patients
-------------------------------------------------------------------

In order to elucidate the prognostic significance of *G9a* expression in GC patients, all participants were followed up for 5 years Kaplan--Meier survival curves were constituted for them. The results of survival analysis showed that patients with high *G9a* expression had poorer overall survival than those with low expression (log-rank test, *P* \< .05) (Fig. [3](#F3){ref-type="fig"}) and that the median OS was 24 months. Moreover, multivariate Cox regression analysis revealed that increased expression of *G9a* was an independent prognostic factor for GC (OS: HR = 3.912, 95% CI = 2.213--6.915; *P* \< .001; PFS: HR = 4.070, 95%CI = 2.310--7.199, Table [2](#T2){ref-type="table"}). In other words, increased *G9a* expression signified poor prognosis of GC. Moreover, ROC curve showed that the sensitivity and specificity of *G9a* in GC diagnosis were 82.4% and 97.2%, respectively, while the area under the curve (AUC) was 0.954 with 95%CI (0.931--0.977), and the diagnosis cut-off value was 1.515 (Fig. [4](#F4){ref-type="fig"}).

![Kaplan--Meier survival curves based on the expression of *G9a* in GC patients.](medi-98-e18212-g004){#F3}
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![ROC curve analysis, sensitivity was as ordinate and 1-specificity was as abscissa. The area under the curve (AUC) was calculated to express the diagnosis value of *G9a* the sensitivity and specificity were 82.4% and 97.2%, respectively and AUC was 0.954 (0.931--0.977). The diagnosis cut-off value of *G9a* in GC was 1.515.](medi-98-e18212-g006){#F4}

4. Discussion
=============

GC is considered as a serious disease threatening human health and reducing the patients' quality of life. Its mortality rate is fairly high, especially in East Asia where more than half of total deaths caused by this malignancy appear.^\[[@R20]\]^ Evidences demonstrate that early diagnosis of GC is rare due to the lack of clinical manifestations at early stage,^\[[@R21]\]^ which leads to miserable outcomes among the cases. Despite advances in therapeutic strategies, such as clinical surgery, and chemo and radiation therapies, the prognosis of GC remains dismal.^\[[@R22]\]^ Therefore, novel molecular markers should be exploited to improve the prognosis and treatment of GC. Currently, various prognostic markers have been proposed for GC. For example, Sun et al showed that the expressions of CDK5 and p27 were downregulated in GC cases and related to the poor prognosis of GC.^\[[@R23]\]^ Yong et al found that RNA-binding motif 4 (*RBM4*) expression was significantly down-regulated in GC tissues and was also associated with GC prognosis.^\[[@R24]\]^ In the present study, we investigated *G9a* expression and its prognostic potential in GC patients.

*G9a* is a euchromatic methyltransferase, and involved in gene silencing via the methylation of histone 3 lysine 9.^\[[@R25]\]^ Reportedly, it can combine with other transcription factors to manage the expression of certain genes.^\[[@R26]\]^*G9a* was reported to regulate cellular activities, such as cell autophagy, proliferation, Epithelial-Mesenchymal Transition (EMT), specific responses to hypoxia, and metabolic changes.^\[[@R27]--[@R29]\]^ Recently, *G9a* dysregulation has been investigated in many human cancers. For instance, *G9a* expression was found to be upregulated in head and neck squamous cell carcinoma tissues and was proved to serve as a novel therapeutic target in this cancer.^\[[@R30]\]^ Francesco and his colleagues detected the role of *G9a* in human cancers, and implied that *G9a* was involved in the initiation and progression of different cancers.^\[[@R11]\]^ In addition, Chen et al revealed that *G9a* represented an effective antineoplastic target.^\[[@R31]\]^ Consequently, we considered that there might be a potential association between *G9a* and GC prognosis.

In the current study, we detected the expression level of *G9a* mRNA using qRT-PCR for paired GC and adjacent noncancerous tissue samples. The results showed *G9a* expression was significantly up-regulated in GC tissues compared with normal ones, which was in accordance with findings in the previous study of Lin et al.^\[[@R19]\]^ Moreover, we examined the influences of clinicopathological features on *G9a* expression in patients with GC. The results revealed that *G9a* expression was influenced by tumor differentiation, lymph node metastasis and TNM stage. However, age, gender, disease type, and pathological type were not correlated with *G9a* expression. These results implied *G9a* might be involved in the progression of GC.

In the current study, we focused on the prognostic value of *G9a* expression in GC. Kaplan--Meier survival curves demonstrated that overall survival was shorter among patients with high levels of *G9a* than those with low *G9a* expression. In order to further verify the prognostic value of *G9a*, multivariate Cox regression was conducted, which revealed *G9a* might be an effective prognostic marker for GC. Showing a polyfactorial and multi-step process, GC is influenced by multiple genetic and environmental factors. So, it is difficult for only 1 factor to independently predict GC prognosis. Moreover, until now, multiple factors have been reported to be associated with GC prognosis, and G9a was also an effective prognostic factor for this malignancy in our study. G9a combining with other factors may exactly predict the prognosis of GC, but this matter needs to be explored in further study.

In this research, we conducted a preliminary analysis on the prognostic significance of G9a in GC. However, some limitations should be noted. The sample size was relatively small and might cause certain bias in final results. In this study, GC tissues and adjacent normal ones were detected, but those from healthy people were not considered due to difficulty in sampling. The influence of G9a on some reported major genes for GC was not explored. Therefore, in further studies, we will verify the results in this study, based on better design, more consideration of the above limitations and larger sample size.

In conclusion, *G9a* expression was upregulated in GC and correlated with the disease progression. The overexpression of *G9a* was a prognostic biomarker for GC. Although *G9a* expression is proved to be a crucial indicator in GC, its molecular mechanisms need to be exploited in further studies.
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